Infanrix-Ipv

Poliovirus type 3 (inactivated) and pertussis filamentous haemagglutinin, the active ingredient in Infanrix-Ipv, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity to prevent poliomyelitis caused by poliovirus type 3 and pertussis (whooping cough) in infants and children.

GNH USA supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and compliance with cold‑chain requirements for vaccine integrity. We adhere to stringent quality standards and regulatory guidelines to support immunization programs across diverse regions.

Infanrix-Ipv is a combination vaccine used in the prevention of viral and bacterial respiratory infections. - Poliomyelitis (type 3): provides immunity that prevents infection by poliovirus type 3. - Pertussis (whooping cough): stimulates protective antibodies against Bordetella pertussis. - Infants and young children: integrates dual protection into the routine childhood immunization schedule.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema that resolves within a few days. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Irritability: temporary fussiness in infants. - Decreased appetite: mild reduction in feeding after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: febrile or non‑febrile convulsions following vaccination. - High fever (>40 °C): may indicate a systemic reaction. - Encephalopathy: rare inflammation of the brain. - Guillain‑Barré syndrome: extremely uncommon autoimmune neuropathy.

Before administering Infanrix-Ipv, consider the following precautions: - Severe allergy screening: do not give to individuals with known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination if the patient has a moderate or severe febrile illness. - Febrile seizures: monitor infants closely for signs of seizures after immunization. - Live vaccine timing: avoid co‑administration with live attenuated vaccines unless specifically recommended. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix-Ipv may interact with other agents as follows: Major Interactions (Avoid): - Live attenuated vaccines: avoid administering within 4 weeks before or after Infanrix-Ipv. - Immunoglobulins or blood products: may diminish the vaccine‑induced immune response. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): can mask post‑vaccination fever, monitor temperature. - Immunosuppressive therapy: may reduce the effectiveness of the vaccine. - Pregnancy: no specific interaction, but consult healthcare provider before use.